Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 25, 2023

The Effect of Low HER2 Expression on Outcomes in Patients With Metastatic HR+ Breast Cancer Treated With a CDK4/6 Inhibitor and Endocrine Therapy

The Breast


Additional Info

The Breast
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
Breast 2023 Aug 01;70(xx)56-62, E Caliskan Yildirim, E Atag, E Coban, O Umit Unal, A Celebi, M Keser, M Uzun, M Keskinkilic, E Tanrikulu Simsek, M Sari, T Yavuzsen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading